Last $37.39 USD
Change Today +0.39 / 1.05%
Volume 6.7K
CBPO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

china biologic products inc (CBPO) Snapshot

Open
$36.79
Previous Close
$37.00
Day High
$37.39
Day Low
$36.65
52 Week High
02/20/14 - $38.60
52 Week Low
06/7/13 - $19.10
Market Cap
873.7M
Average Volume 10 Days
15.3K
EPS TTM
$1.95
Shares Outstanding
23.4M
EX-Date
--
P/E TM
19.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA BIOLOGIC PRODUCTS INC (CBPO)

Related News

No related news articles were found.

china biologic products inc (CBPO) Related Businessweek News

No Related Businessweek News Found

china biologic products inc (CBPO) Details

China Biologic Products, Inc., a biopharmaceutical company, is engaged in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. It offers human albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human albumin and human immunoglobulin for intravenous injection (IVIG) products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative heating; and Human coagulation factor VIII for the treatment of coagulopathie, such as hemophilia A. The company’s products under development comprise human prothrombin complex concentrate; human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; Varicella hyperimmune globulins; immune globulin intravenous, Caprylate/Chromatography virus filtration; and human antithrombin III. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

1,467 Employees
Last Reported Date: 03/12/14

china biologic products inc (CBPO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $626.9K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $199.2K
Senior Corporate Vice President and Corporate...
Total Annual Compensation: $157.6K
Corporate Vice President
Total Annual Compensation: $132.2K
Compensation as of Fiscal Year 2012.

china biologic products inc (CBPO) Key Developments

China Biologic Products, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for 2014

China Biologic Products, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. Total sales in the fourth quarter of 2013 were $42.6 million, representing an increase of 25.3% from $34.0 million in the same quarter of 2012. The increase was mainly due to the substantial increase in albumin sales in Shandong and increased sales from Placenta Polypeptide in Guizhou. Income from operations decreased by 10.4% to $12.5 million from $13.9 million in the same quarter of 2012 for the reasons states above. Net income attributable to the Company increased by 52.0% to $8.8 million from $5.8 million in the same quarter of 2012. Fully diluted net income per share was $0.32 in the fourth quarter of 2013 compared to $0.21 in the same quarter of 2012. Non-GAAP adjusted net income attributable to the Company was $9.6 million, or $0.35 per diluted share, in the fourth quarter of 2013, representing a 32.2% increase from $7.3 million, or $0.27 per diluted share, in the fourth quarter of 2012. Total sales in 2013 were $203.4 million, an increase of 10.0% from $184.8 million in 2012. Excluding foreign exchange influence, the increase in sales was primarily attributable to a mix of price and volume increases in certain plasma based products. Income from operations in 2013 was $86.9 million, representing an increase of 16.7% from $74.5 million in 2012. Operating margin increased to 42.7% in 2013 from 40.3% in 2012. Net income attributable to the Company was increased by 20.7% to $54.6 million in 2013, from $45.2 million in 2012. Net margins were 26.9% and 24.5% for the years ended December 31, 2013 and 2012, respectively. Fully diluted net income per share was $1.96, as compared to $1.62 in 2012. Non-GAAP adjusted net income attributable to the Company was $59.0 million or $2.12 per diluted share in 2013, compared to $48.0 million or $1.79 per diluted share in 2012. Earnings before income tax expense was $92.401 million compared to $81.135 million for the same period a year ago. Net cash provided by operating activities for the year ended December 31, 2013 was $74.3 million, as compared to $71.1 million for the same period of 2012. Payment for property, plant and equipment was of $20.492 million compared to $13.886 million for the same period a year ago. Payment for intangible assets and land use rights was of $1.327 million compared to $14.059 million for the same period a year ago. For the full year of 2014, the Company expects total sales to be in the range of $230 million to $240 million. This guidance assumes only organic growth and excludes acquisitions and necessarily assumes no significant adverse price changes during 2014. The Company estimates full year non-GAAP adjusted net income to be in the range of $67 million to $69 million.

China Biologic Products, Inc., Q4 2013 Earnings Call, Mar 13, 2014

China Biologic Products, Inc., Q4 2013 Earnings Call, Mar 13, 2014

China Biologic Products, Inc. to Report Q4, 2013 Results on Mar 12, 2014

China Biologic Products, Inc. announced that they will report Q4, 2013 results at 5:00 PM, China Standard Time on Mar 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBPO:US $37.39 USD +0.39

CBPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Beijing Tiantan Biological Products Co CNY18.97 CNY +0.28
Hualan Biological Engineering Inc CNY27.05 CNY +0.10
Jiangxi Boya Bio-Pharmaceutical Co Ltd CNY44.84 CNY +0.19
Shanghai RAAS Blood Products Co Ltd CNY59.28 CNY +5.39
View Industry Companies
 

Industry Analysis

CBPO

Industry Average

Valuation CBPO Industry Range
Price/Earnings 18.8x
Price/Sales 4.7x
Price/Book 4.0x
Price/Cash Flow 15.8x
TEV/Sales 3.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA BIOLOGIC PRODUCTS INC, please visit www.chinabiologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.